{"id":13100,"date":"2023-05-09T04:30:00","date_gmt":"2023-05-09T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-3\/"},"modified":"2023-05-09T04:30:00","modified_gmt":"2023-05-09T08:30:00","slug":"dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-3","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-3\/","title":{"rendered":"DBV Technologies invit\u00e9e \u00e0 participer \u00e0 une prochaine Conf\u00e9rence Investisseur"},"content":{"rendered":"<div class=\"pr-date-globe\">May 09, 2023 16:30 ET<\/div>\n<p>                            <!-- <span>Name:DistributionId<\/span>   <span>Value:1000809079<\/span> -->                            <!-- <span>Name:EnableQuoteCarouselOnPnr<\/span>   <span>Value:False<\/span> -->                            <!-- <span>Name:IcbCode<\/span>   <span>Value:4573<\/span> -->                            <!-- <span>Name:CustomerId<\/span>   <span>Value:1011152<\/span> -->                            <!-- <span>Name:HasMediaSnippet<\/span>   <span>Value:false<\/span> -->                            <!-- <span>Name:AnalyticsTrackingId<\/span>   <span>Value:66855c3b-d939-4e39-9a1d-4a15df48b44c<\/span> --><\/p>\n<p align=\"right\">Montrouge, France, 9 mai (22h 30 CEST), 2023<\/p>\n<p align=\"justify\"><strong>DBV Technologies invit\u00e9e \u00e0 participer \u00e0 une<\/strong> <strong>prochaine<\/strong> <strong>Conf\u00e9rence Investisseur<\/strong><\/p>\n<p align=\"justify\">DBV Technologies (Euronext : DBV &#8211; ISIN : FR0010417345 &#8211; Nasdaq Stock Market : DBVT), une soci\u00e9t\u00e9 biopharmaceutique au stade clinique, a annonc\u00e9 aujourd&rsquo;hui sa participation \u00e0 la conf\u00e9rence JMP Securities Life Sciences qui se tiendra les 15 et 16 mai \u00e0 New York, NY. Daniel Tass\u00e9, Directeur G\u00e9n\u00e9ral, fera une pr\u00e9sentation de la soci\u00e9t\u00e9 le lundi 15 mai 2023 \u00e0 15 h (CEST) et participera \u00e0 des rencontres individuelles avec des investisseurs tout au long de la journ\u00e9e.<\/p>\n<p align=\"justify\">Une retransmission en direct de la pr\u00e9sentation de la Soci\u00e9t\u00e9 sera disponible dans<br \/>la section Investisseurs et m\u00e9dias du site Web de la soci\u00e9t\u00e9 :<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gF0DDONYc5akjoeyGMqlXAiEMI-8pzuPquZuPWt9FL5rtOSI0Aa3eX-dJyznrncIKe7vaP_Vr7Cgdtlt97XPEEPHshiu3JPwl6D1tDAc9a9C57VopyQpVVgklHtaaY_YlfwMJ_tDB5a6Rh7IwEqh-fZXUa9Mmb4BBrcjL-bP2WY=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.dbv-technologies.com\/investor-relations\/<\/a>.<\/p>\n<p align=\"justify\">L\u2019enregistrement sera \u00e9galement disponible pendant 90 jours apr\u00e8s l\u2019\u00e9v\u00e8nement<br \/>sur le site internet de DBV Technologies.<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p align=\"justify\"><strong>A propos de DBV Technologies<\/strong><br \/>DBV&nbsp;Technologies d\u00e9veloppe Viaskin\u2122, une plateforme technologique exclusive exp\u00e9rimentale avec de larges applications potentielles en immunoth\u00e9rapie. Viaskin est bas\u00e9 sur l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e, ou EPIT\u2122, et constitue la m\u00e9thode de DBV&nbsp;Technologies pour d\u00e9livrer des compos\u00e9s biologiquement actifs au syst\u00e8me immunitaire \u00e0 travers la peau intacte. Avec cette nouvelle classe de produits candidats non invasifs, la Soci\u00e9t\u00e9 vise \u00e0 transformer en toute s\u00e9curit\u00e9 le traitement des patients souffrant d\u2019allergies alimentaires. Les programmes de DBV&nbsp;Technologies sur les allergies alimentaires comprennent des essais cliniques en cours sur Viaskin Peanut. Le si\u00e8ge mondial de DBV&nbsp;Technologies est situ\u00e9 \u00e0 Montrouge, en France, et ses op\u00e9rations nord-am\u00e9ricaines sont bas\u00e9es \u00e0 Basking Ridge, NJ. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment&nbsp;B d\u2019Euronext Paris (symbole&nbsp;: DBV, code ISIN&nbsp;: FR0010417345) et les ADS de la Soci\u00e9t\u00e9 (chacun repr\u00e9sentant une demi-action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Global Select Market (symbole&nbsp;: DBVT).<\/p>\n<p align=\"justify\"><strong>D\u00e9clarations prospectives<\/strong><br \/>Le pr\u00e9sent communiqu\u00e9 de presse peut contenir des d\u00e9clarations prospectives et des estimations, notamment des d\u00e9clarations concernant le potentiel th\u00e9rapeutique de Viaskin\u2122 Peanut en tant que traitement pour les enfants allergiques aux arachides et les avantages potentiels de l\u2019EPIT\u2122. Ces d\u00e9clarations et estimations prospectives ne constituent ni des promesses ni des garanties et comportent des risques et des incertitudes substantiels et celles-ci peuvent \u00eatre affect\u00e9s par les conditions du march\u00e9 ainsi que par d\u2019autres risques et incertitudes expos\u00e9s dans les documents r\u00e9glementaires d\u00e9pos\u00e9s par DBV Technologies aupr\u00e8s de l\u2019Autorit\u00e9 des March\u00e9s Financiers (\u00ab AMF \u00bb) ainsi que dans les documents et rapports d\u00e9pos\u00e9s par DBV Technologies aupr\u00e8s de la Securities and Exchange Commission (\u00ab SEC \u00bb) des \u00c9tats-Unis, et dans les documents et rapports futurs d\u00e9pos\u00e9s aupr\u00e8s de l\u2019AMF et de la SEC. Les investisseurs actuels et potentiels sont invit\u00e9s \u00e0 ne pas accorder une confiance excessive \u00e0 ces d\u00e9clarations et estimations prospectives, qui ne sont valables qu\u2019\u00e0 la date du pr\u00e9sent document. \u00c0 l\u2019exception de ce qui est requis par la loi applicable, DBV Technologies ne s\u2019engage nullement \u00e0 mettre \u00e0 jour ou \u00e0 r\u00e9viser les informations contenues dans le pr\u00e9sent communiqu\u00e9 de presse<strong>.<\/strong><\/p>\n<p align=\"justify\"><strong>Investor Contact<\/strong><strong>s<\/strong><br \/>Kevin Gardner<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3OFeIOd1C62ybCxdE272jS5zqRnA1Y48aZeg9Yug_bd0hRgOG1xIvrec9kRNqqAA31Dvu1XtKlNyn_xUD1AOvxotVdz2_ET33o4NWRHPvJUMzrWtOj5PLD4bNnmZXm1V\" rel=\"nofollow noopener\" target=\"_blank\" title=\"kgardner@lifesciadvisors.com\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p align=\"justify\">Chris Calabrese<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ij4Chyj3ve5i1J1fkjE4QXq2Zw9mDgQp_Ioy-8umu7o3KeDsAmaIORGt3yae51lnQkIt-Xiz7bzf9GO2go2MPH0cGQtAv6NZLUJrMyxW7kEKX1DV2L4TVzkdybmmPzQM\" rel=\"nofollow noopener\" target=\"_blank\" title=\"ccalabrese@lifesciadvisors.com\">ccalabrese@lifesciadvisors.com<\/a><\/p>\n<p align=\"justify\"><strong>Media Contact<\/strong><br \/>Angela Marcucci<br \/>DBV Technologies<br \/>+1&nbsp;646-842-2393<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mzUDpHhE2ybwbgDcdmOvoKNSuRX9IRLl65mLWZbkP6qnfZDXdKX7KH0QrmxcSFryeRPI4I3pV2uw_LIV2mgPu1NbWuY7x38hQFQgbECpQz38iV_HSqWf19eqEa-Xi8TxacjrkKduyMXCUVaThwWniA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"angela.marcucci@dbv-technologies.com\">angela.marcucci@dbv-technologies.com<\/a>&nbsp;<\/p>\n<p align=\"justify\">Viaskin and EPIT are trademarks of DBV Technologies.<\/p>\n<\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=rH4JyhwhEp06-ZOSy7Sqi6218b_tnO5JaR4Th3vjXlkB5NgCqPeFmh9Ic3r5Mt2b-yV-5izTS0XO_07GsRlXnszOEuAZw2Ahg0GUnoTyC-jl0Cwgs_8kn57yMtVJQ9uCsevta1-fnnnIBx88_-XhBNMv4i8wFhG-lAiTUt8n2m0=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/NjY4NTVjM2ItZDkzOS00ZTM5LTlhMWQtNGExNWRmNDhiNDRjLTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">        <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-13100","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/13100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/13100\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=13100"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=13100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}